Why the study?
The role of pre-implantation inflammatory condition assessed using routine laboratory tests in CRT recipients has been rarely investigated.
Does cardiac resynchronization therapy improve indirect inflammatory markers in patients with HFrEF and prolonged QRS?
Cohort (n=75)
Single-blind
No
Does cardiac resynchronization therapy improve indirect inflammatory markers in patients with HFrEF and prolonged QRS?
May indicate anti-inflammatory CRT effects; hypothesis-generating and requires outcome validation before clinical use.
Background: Cardiac resynchronization therapy (CRT) is an established treatment for patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) and prolonged QRS despite optimal pharmacological therapy. Inflammation plays a crucial role in the pathogenesis and progression of cardiovascular disease. The role of CRT pre-implantation inflammatory condition assessed using routine laboratory tests has been rarely investigated.
No takes yet. Share an insight, caveat, or question.
Çoksevim et al. (2020) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=75). Cardiac Resynchronization Therapy (CRT) vs. Baseline (pre-CRT) was evaluated on Neutrophil-to-lymphocyte ratio (NLR) (p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Archives of Current Medical Research